Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial - Davies, M A; Saiag, P; Robert, C (Lancet Oncol, 2017)